Journal Watch · Frontiers in Immunology · 2026

Characteristics and research waste of immunotherapy randomized clinical trials: a cross-sectional analysis.

These findings underscore the urgent need to prioritize large-scale collaborative frameworks to optimize resource allocation and ensure reliable clinical evidence.

Li J, Wang S, Zhou Q et al.Frontiers in Immunology4 min readPharma relevance 65/100

DOI: 10.3389/fimmu.2026.1845591PMID: 42676491Study type: randomised / controlled clinical trial

TL;DR

These findings underscore the urgent need to prioritize large-scale collaborative frameworks to optimize resource allocation and ensure reliable clinical evidence.

Key findings

  • Multivariate analysis revealed that non-tumor diseases (adjusted OR = 0.29, 95% CI: 0.09-0.85, P = 0.028) and a quadruple-blind design (adjusted OR = 4.84, 95% CI: 1.71-14.90, P = 0.004) were significantly associated with publication status.
  • Univariable analysis revealed that non-tumor diseases (OR = 4.36, 95% CI: 2.02-9.57, P<0.001) and European principal investigators (PIs) (OR = 3.48, 95% CI: 1.49-8.16, P = 0.004) were positively correlated with waste, whereas international recruitment (OR = 0.16, 95% CI: 0.07-0.36, P<0.001), multicenter design (OR = 0.14, 95% CI: 0.05-0.35, P<0.001), and large sample size (OR = 0.27, 95% CI: 0.12-0.60, P = 0.001) were negatively correlated.
  • After adjustment, non-tumor diseases remained a risk factor (OR = 3.84, 95% CI: 1.18-13.54, P = 0.029), whereas a multicenter design had a strong protective effect (OR = 0.07, 95% CI: 0.00-0.57, P = 0.030).<h4>Conclusions</h4>This study revealed a high incidence of research waste in immunotherapy RCTs, which was predominantly driven by non-tumor studies.
  • These findings underscore the urgent need to prioritize large-scale collaborative frameworks to optimize resource allocation and ensure reliable clinical evidence.

Numbers at a glance (from the abstract)

77.4%45.1%54.9%95%P = 0.028P = 0.004P<0.001P = 0.001P = 0.029P = 0.030

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Research waste was defined as non-publication, inadequate reporting (CONSORT 2010), or avoidable design flaws (Cochrane Risk of Bias Tool). Associations between study characteristics and outcomes (publication status and waste) were evaluated using logistic regression.<h4>Results</h4>Among the 164 RCTs analyzed, 127 (77.4%) exhibited research waste. With respect to publication status, 74 (45.1%) were published, and 90 (54.9%) were unpublished.

Full abstract (original)

Background: <h4>Background</h4>Immunotherapy spans tumor and non-tumor disciplines, yet the surge in randomized controlled trials (RCTs) has not yielded proportional improvements in evidence quality, leading to substantial research waste. In this study, the immunotherapy RCT landscape was characterized, and the prevalence and risk factors for research waste were quantified.<h4>Methods</h4>This registry-based cross-sectional study analyzed phase III/IV immunotherapy RCTs from ClinicalTrials.gov. The publication status was verified via PubMed, Scopus, and Google Scholar.

What they did: Research waste was defined as non-publication, inadequate reporting (CONSORT 2010), or avoidable design flaws (Cochrane Risk of Bias Tool). Associations between study characteristics and outcomes (publication status and waste) were evaluated using logistic regression.<h4>Results</h4>Among the 164 RCTs analyzed, 127 (77.4%) exhibited research waste. With respect to publication status, 74 (45.1%) were published, and 90 (54.9%) were unpublished.

Results & conclusions: Multivariate analysis revealed that non-tumor diseases (adjusted OR = 0.29, 95% CI: 0.09-0.85, P = 0.028) and a quadruple-blind design (adjusted OR = 4.84, 95% CI: 1.71-14.90, P = 0.004) were significantly associated with publication status. Univariable analysis revealed that non-tumor diseases (OR = 4.36, 95% CI: 2.02-9.57, P<0.001) and European principal investigators (PIs) (OR = 3.48, 95% CI: 1.49-8.16, P = 0.004) were positively correlated with waste, whereas international recruitment (OR = 0.16, 95% CI: 0.07-0.36, P<0.001), multicenter design (OR = 0.14, 95% CI: 0.05-0.35, P<0.001), and large sample size (OR = 0.27, 95% CI: 0.12-0.60, P = 0.001) were negatively correlated. After adjustment, non-tumor diseases remained a risk factor (OR = 3.84, 95% CI: 1.18-13.54, P = 0.029), whereas a multicenter design had a strong protective effect (OR = 0.07, 95% CI: 0.00-0.57, P = 0.030).<h4>Conclusions</h4>This study revealed a high incidence of research waste in immunotherapy RCTs, which was predominantly driven by non-tumor studies. These findings underscore the urgent need to prioritize large-scale collaborative frameworks to optimize resource allocation and ensure reliable clinical evidence.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1845591 · PubMed 42676491.

Why it matters for pharma & biotech

  • Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
  • Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

These findings underscore the urgent need to prioritize large-scale collaborative frameworks to optimize resource allocation and ensure reliable clinical evidence.

What type of study is this?

It is a randomised / controlled clinical trial, published in Frontiers in Immunology in 2026. Research waste was defined as non-publication, inadequate reporting (CONSORT 2010), or avoidable design flaws (Cochrane Risk of Bias Tool).

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1845591. PubMed ID: 42676491. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Li J, Wang S, Zhou Q et al.. Characteristics and research waste of immunotherapy randomized clinical trials: a cross-sectional analysis.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1845591.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/characteristics-and-research-waste-of-immunotherapy-randomized-clinical-845591/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides